Biodesix: Strong Execution, Margin Expansion, and Path to Profitability Support Buy Rating and $20 Target

Analyst Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Biodesix and keeping the price target at $20.00.

Kyle Mikson CFA has given his Buy rating due to a combination of factors, including Biodesix’s strong quarterly execution and improving financial profile. The company delivered robust revenue growth in 4Q25, driven by higher lung diagnostic testing volumes, firmer pricing, and materially better margins that together produced its first quarter of positive adjusted EBITDA and a significantly lower cash burn.

Mikson also highlights management’s 2026 revenue guidance, which implies healthy double‑digit growth supported by a larger, increasingly productive sales force and sustained gross margin strength. In his valuation work, he assumes attractive long‑term growth and margin expansion, and notes that the current share price offers meaningful upside to his $20 target, reinforced by improved liquidity and a clearer path toward profitability.

Mikson CFA covers the Healthcare sector, focusing on stocks such as Illumina, GeneDx Holdings, and Biodesix. According to TipRanks, Mikson CFA has an average return of 0.8% and a 38.36% success rate on recommended stocks.

In another report released on February 27, TD Cowen also reiterated a Buy rating on the stock with a $30.00 price target.